Quizartinib

Quizartinib
Generic Name/API:Quizartinib
Packaging:Cartons containing 14 x 1, 28 x 1 or 56 x 1 film-coated tablets
Storage:Store at 20°C to 25°C
Dosage:For dosage information, please check the General Information section.
Strength:Tablets: 17.7 mg or 26.5 mg.
Indication:Vanflyta is a kinase inhibitor indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test

VANFLYTA (Quizartinib) is a  highly selective oral targeted therapy primarily used in the treatment of Acute Myeloid Leukemia (AML). Specifically, it is indicated for adult patients whose AML cells carry a particular genetic alteration known as a FLT3-ITD (FMS-like tyrosine kinase 3 internal tandem duplication) mutation. As a potent FLT3 inhibitor, Vanflyta works by blocking the activity of the mutated FLT3 receptor, which is often overactive in FLT3-ITD positive AML and drives the uncontrolled growth and survival of leukemia cell.

STRENGTH:

Tablets: 17.7 mg or 26.5 mg.

DOSAGE:  

VANFLYTA Initiation

 Induction* Consolidation† Maintenance
Starting on Day 8

(for 7 + 3 regimen)‡

 Starting on Day 6

Starting on Day 1
Dose 35.4 mg orally once daily 35.4 mg orally once daily
  • Administer 26.5 mg orally once daily Days 1 through 14 of the first cycle if QTcF is less than or equal to 450 ms.
  • Increase the dose to 53 mg once daily on Day 15 of the first cycle if QTcF is less than or equal to 450 ms. Maintain the 26.5 mg once daily dose if QTcF greater than 500 ms was observed during induction or consolidation.
Duration

(28-day cycles)

 Two weeks in each cycle (Days 8 to 21)‡ Two weeks in each cycle (Days 6 to 19)
  • Once daily with no break between cycles for up to 36 cycles
  • Patients can receive up to 2 cycles of induction.
  • Patients can receive up to 4 cycles of consolidation.
  • For 5 + 2 regimen as the second induction cycle, VANFLYTA will be given on Days 6 to 19.

ADVERSE  EFFECTS 

  1. Blood and Lymphatic System Disorders 
    • Febrile neutropenia
    • Neutropenia
    • Thrombocytopenia†
    • Anemia
  2.  Gastrointestinal Disorders 
    • Diarrheaa 
    • Mucositisb 
    • Nausea 
    • Abdominal pain
    •  Vomiting
    •  Dyspepsia 
  3. Infections and Infestations 
    • Sepsisc, 
    • Upper respiratory tract infection
    • Fungal infectiond, 
    •  Herpesvirus infections
  4. Nervous System Disorders 
    • Headache
  5. Hepatobiliary disorders 
    • Hypertransaminasemia

STORAGE : 

Store at 20°C to 25°C

  • QT Prolongation, Torsades de Pointes, and Cardiac Arrest
  • VANFLYTA REMS
  • Embryo-Fetal Toxicity

 

 

Process to Import Medicine

FAQ

Vanflyta is a prescription medicine used to treat adult patients with Acute Myeloid Leukemia (AML) that has a specific genetic mutation called FLT3-ITD (FMS-like tyrosine kinase 3 internal tandem duplication). It is typically used in patients whose AML has either relapsed (returned after treatment) or is refractory (did not respond to previous treatment).

Vanflyta belongs to a class of drugs called FLT3 inhibitors. It works by blocking the activity of the mutated FLT3 protein, which is an abnormal protein found in some AML cells. By inhibiting this protein, Vanflyta helps to stop the growth and spread of leukemia cells, leading to their death.

Vanflyta is an oral medication taken as a tablet once daily, with or without food. It is usually taken continuously for as long as the patient is benefiting from the treatment or until unacceptable toxicity occurs.

Common side effects can include nausea, vomiting, diarrhea, fatigue, muscle and joint pain (arthralgia/myalgia), anemia (low red blood cell count), thrombocytopenia (low platelet count), and neutropenia (low white blood cell count). Your doctor will monitor your blood counts regularly.

Serious side effects can include QTc prolongation (a potentially dangerous heart rhythm disorder), myelosuppression (severe lowering of blood counts), and liver problems. Patients require regular electrocardiogram (ECG) monitoring to check heart rhythm and liver function tests before and during treatment.

FLT3-ITD is a specific genetic mutation found in the FLT3 gene in some AML patients. This mutation leads to an overactive FLT3 protein, which drives uncontrolled growth of leukemia cells. Vanflyta is designed to specifically target and inhibit this mutated protein, making it a personalized treatment for patients with this specific genetic alteration.

The cost of vanflyta (quizartinib) in India varies since it is not locally available and must be imported. Factors such as supplier availability, import charges, and currency fluctuations affect the final price. For the latest cost details, contact 24/7QualityMeds at +91 9967979080.

To buy vanflyta (quizartinib) online in India at a genuine price, reach out to 24/7QualityMeds. We assist patients with legal import procedures and ensure safe, timely delivery at the best possible price.

While selecting a supplier, we essentially ensure that the supplier holds a valid Good Distribution Practice (GDP) certificate and possesses a valid operating license. These credentials confirm the suppliers adherence to International standards for the proper distribution of medicinal product.

Related products